A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).

Harding, James J.; Erinjeri, Joseph P.; Tan, Benjamin; Reiss, Kim A.; Mody, Kabir; Khalil, Daniel; Yarmohammadi, Hooman; Nadolski, Gregory J.; Giardina, Joseph D.; Capanu, Marinela; Richard, K. G.; Bradley, Mikaela; Boussayoud, Chayma; Valentino, Emily; Merghoub, Taha; Jarnagin, William R.; Soulen, Michael C.; Brown, Karen T.; Abou‐Alfa, Ghassan K.

doi:10.1200/jco.2018.36.15_suppl.tps4146

Cited by 13 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2018, the ASCO meeting reported a multicenter, phase I trial of nivolumab with DEB-TACE in unresectable HCC that aimed to evaluate the safety and tolerability of combined therapies. The IMMUTACE study (NCT03572582) was a phase II trial in Germany focusing on DEB-TACE and nivolumab (75).…”

Section: Combination Immunotherapy With Locoregional Therapy In Hccmentioning

confidence: 99%

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review)

2020

View full text Add to dashboard Cite

In recent years, the incidence of liver cancer has increased and is currently the sixth most common tumor and the second leading cause of cancer-associated mortality worldwide. Most cases of liver cancer are hepatocellular carcinoma (HCC). Surgery, including liver transplantation or resection, and radiofrequency ablation therapies are all considered to be the curative treatment options for early-stage HCC. However, most patients have advanced HCC at the time of diagnosis, contributing to a poor prognosis. Therefore, improved treatment for late-stage HCC is needed. Immune checkpoint inhibitors (ICIs), among which programmed death receptor 1 (PD-1)/PD-ligand 1 and cytotoxic T lymphocyte-associated protein 4 are the representative immunological checkpoints, have shown great promise and progress for HCC treatment. The present review summarizes recent studies that have focused on ICIs and discusses the present limitations affecting the development of new therapeutic strategies.

show abstract

Section: Combination Immunotherapy With Locoregional Therapy In Hccmentioning

confidence: 99%

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review)

2020

View full text Add to dashboard Cite

show abstract

“…44 Patients with HCC (32 patients) or biliary tract carcinoma (9 patients) were treated with TACE, radiofrequency ablation, or cryoablation in combination with tremelimumab. 45 The study is actively accruing (ClinicalTrials.gov identifier NCT03143270). Tumor biopsy at 6 weeks suggested that the clinical response was associated with activation of CD4-positive and CD8-positive T cells.…”

Section: Local Therapies and Checkpoint Inhibitorsmentioning

confidence: 99%

“…Correlative objectives include sequential whole-blood sampling and biopsies (pretreatment, while receiving treatment, and at the time of disease progression) to define mechanisms of anti-PD-1 resistance. 45 The study is actively accruing (ClinicalTrials.gov identifier NCT03143270).…”

Section: Local Therapies and Checkpoint Inhibitorsmentioning

confidence: 99%

Immune checkpoint inhibitors for hepatocellular carcinoma

Dika

Khalil

Abou‐Alfa

2019

Cancer

View full text Add to dashboard Cite

The position of immunotherapy as a pillar of systemic cancer treatment has been firmly established over the past decade. Immune checkpoint inhibitors are a welcome option for patients with different malignancies. This is in part because they offer the possibility of durable benefit, even for patients who have failed other treatment modalities. The recent demonstration that immunotherapy is effective for patients with hepatocellular carcinoma (HCC) is a milestone in the history of this recalcitrant disease. The treatment of HCC has been a challenge, and for many years was limited to the tyrosine kinase inhibitor sorafenib and to several novel tyrosine kinase inhibitors that have shown efficacy and have been approved. The current role of immune checkpoint inhibitors in the management of HCC, and how this role is likely to evolve in the years ahead, are key. Other than efforts evaluating single checkpoint inhibitors, potential combination strategies, including combinations with existing local and systemic approaches, including novel therapies are evolving. This is understandably of special interest considering the potential unique immune system of the liver, which may impact the use of immunotherapy in patients with HCC going forward, and how can it be enhanced further. Cancer 2019;125:3312-3319.

show abstract

“…Other locoregional therapies, like transarterial chemoembolization (TACE), have also been explored in combination with immunotherapy. For instance, a multicenter pilot study evaluating the safety of combination of nivolumab with drug-eluting bead-TACE (deb-TACE) in patients with HCC is currently underway [176]. Another study evaluating the safety and efficacy of combination treatment with pembrolizumab and TACE is also ongoing (NCT03397654).…”

Section: Other Icb Combinationsmentioning

confidence: 99%

Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers

Tai

Choo

Chew

2019

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), the most common type of liver cancer, is derived mostly from a background of chronic inflammation. Multiple immunotherapeutic strategies have been evaluated in HCC, with some degree of success, particularly with immune checkpoint blockade (ICB). Despite the initial enthusiasm, treatment benefit is only appreciated in a modest proportion of patients (response rate to single agent ~20%). Therapy-induced immune-related adverse events (irAEs) and economic impact are pertinent considerations with ICB. It is imperative that a deeper understanding of its mechanisms of action either as monotherapy or in combination with other therapeutic agents is needed. We herein discuss the latest developments in the immunotherapeutic approaches for HCC, the potential predictive biomarkers and the rationale for combination therapies. We also outline promising future immunotherapeutic strategies for HCC patients.

show abstract

A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).

Cited by 13 publications

References 0 publications

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review)

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review)

Immune checkpoint inhibitors for hepatocellular carcinoma

Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers

Contact Info

Product

Resources

About